$3.50
3.24% today
Nasdaq, Feb 05, 04:15 pm CET
ISIN
US1628281073
Symbol
CKPT
Sector
Industry

Checkpoint Therapeutics, Inc. Stock price

$3.39
-0.27 7.38% 1M
+1.19 54.09% 6M
+0.19 5.94% YTD
+1.54 83.24% 1Y
-20.51 85.82% 3Y
-15.31 81.87% 5Y
-46.61 93.22% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.22 6.94%
ISIN
US1628281073
Symbol
CKPT
Sector
Industry

Key metrics

Market capitalization $165.54m
Enterprise Value $160.84m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3,216.80
P/S ratio (TTM) P/S ratio 3,310.80
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -72.51%
Revenue (TTM) Revenue $50.00k
EBIT (operating result TTM) EBIT $-37.51m
Free Cash Flow (TTM) Free Cash Flow $-30.76m
Cash position $4.70m
EPS (TTM) EPS $-1.44
P/E forward negative
P/S forward 12,112.39
EV/Sales forward 11,768.49
Short interest 13.37%
Show more

Is Checkpoint Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Checkpoint Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Checkpoint Therapeutics, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Checkpoint Therapeutics, Inc. forecast:

Buy
100%

Financial data from Checkpoint Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.05 0.05
71% 71%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.92 9.92
7% 7%
19,840%
- Research and Development Expense 28 28
44% 44%
55,280%
-38 -38
36% 36%
-75,020%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -38 -38
36% 36%
-75,028%
Net Profit -46 -46
14% 14%
-92,940%

In millions USD.

Don't miss a Thing! We will send you all news about Checkpoint Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Checkpoint Therapeutics, Inc. Stock News

Positive
Seeking Alpha
about 2 months ago
Checkpoint Therapeutics, Inc. received FDA approval for Unloxcyt, the first PD-L1 drug for advanced cSCC, with strong clinical results and a market-disruptive pricing strategy. Despite mixed investor reactions, Unloxcyt's potential $1.6B peak sales and competitive pricing could make it a transformative player in the cSCC market. Risks include high competition, commercialization costs, and poten...
Neutral
GlobeNewsWire
about 2 months ago
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
Positive
Seeking Alpha
3 months ago
Checkpoint Therapeutics, Inc.'s cosibelimab shows promising efficacy and safety in treating cSCC, with a high tumor occupancy rate and strong clinical data. The upcoming PDUFA date on December 28th is crucial, with potential FDA approval driving significant market growth and revenue projections. Despite competitive pressures and financial risks, cosibelimab's unique mechanism and strong IP posi...
More Checkpoint Therapeutics, Inc. News

Company Profile

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.

Head office United States
CEO James Oliviero
Employees 23
Founded 2014
Website www.checkpointtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today